Molecular Mechanisms of Luteolin Against Atopic Dermatitis Based on Network Pharmacology and in vivo Experimental Validation
Liu Tang,Jiefang Gao,Xiaolei Li,Xiaoqin Cao,Benhong Zhou
DOI: https://doi.org/10.2147/DDDT.S387893
2022-12-09
Abstract:Liu Tang, 1 Jiefang Gao, 2 Xiaolei Li, 2 Xiaoqin Cao, 3 Benhong Zhou 1 1 Department of Pharmacy, Renmin Hospital of Wuhan University, Wuhan, People's Republic of China; 2 School of Pharmaceutical Sciences, Wuhan University, Wuhan, People's Republic of China; 3 School of Medicine, Jianghan University, Wuhan, People's Republic of China Correspondence: Liu Tang; Benhong Zhou, Department of Pharmacy, Renmin Hospital of Wuhan University, Wuhan, People's Republic of China, Email ; Purpose: To undercover the underlying mechanisms of luteolin against atopic dermatitis (AD), clinically characterized by recurrent eczematous lesions and intense itching, based on network pharmacology, molecular docking and in vivo experimental validation. Methods: TCMSP, STITCH and SwissTargetPrediction databases were utilized to screen the corresponding targets of luteolin. Targets related to AD were collected from DisGeNET, GeneCards and TTD databases. PPI network of intersection targets was constructed through STRING 11.0 database and Cytoscape 3.9.0 software. GO and KEGG enrichment analysis were performed to investigate the critical pathways of luteolin against AD. Further, the therapeutic effects and candidate targets/signaling pathways predicted from network pharmacology analysis were experimentally validated in a mouse model of AD induced by 2, 4-dinitrofluorobenzene (DNFB). Results: A total of 31 intersection targets were obtained by matching 151 targets of luteolin with 553 targets of AD. Among all, 20 core targets were identified by PPI network topology analysis, including IL-6, TNF, IL-10, VEGFA, IL-4, etc., and molecular docking indicated that luteolin binds strongly to these core targets. KEGG pathway enrichment analysis suggested that the intersected targets were significantly enriched in IL-17 signaling pathway, Th17 cell differentiation, Th1 and Th2 cell differentiation, JAK/STAT signaling pathway, etc. The in vivo experiment validated that luteolin could alleviate AD-like skin symptoms, as evidenced by the lower SCORAD score, the reduced infiltration of mast cells and the recovery of skin barrier function. Furthermore, luteolin restored immune balance by regulating the production of Th1/Th2/Th17-mediated cytokines, which were both the predicted core targets. Moreover, luteolin inhibited the phosphorylation of JAK2 and STAT3 in the lesional skin. Conclusion: Together, the present study systematically clarifies the ameliorative effects and possible molecular mechanisms of luteolin against AD through the combination of network pharmacology and experimental validation, shedding light on the future development and clinical application of luteolin. Keywords: atopic dermatitis, luteolin, network pharmacology, target prediction, experimental validation Atopic dermatitis (AD), a chronic inflammatory and pruritic skin disorder, is characterized by recurrent eczematous and inflamed skin lesions, compromised barrier function and intense itch. 1,2 Itch is burdensome symptom and can negatively influence patients' sleep quality, social life and emotional well-being. The pathogenesis of AD is multifactorial and complex, most researchers hold the view that immunologic aberrations and epidermal barrier dysfunction constitute critical factors in the development of this disease. 3,4 Findings proposed that the Th1/Th2 immune imbalance caused by a predominant Th2 over Th1 immune response has been recognized as a crucial pathogenesis of cutaneous inflammation in AD. Th2-mediated cytokines, such as interleukin (IL)-4, IL-5, IL-13, could activate IgE response to allergens and disrupt skin barrier function. Th17 cells and Th22 cells, another two novel CD4 + T cell subsets, have also been found to be increased in AD lesions and associated with AD severity. 5–7 Current treatment options for AD are limited and mainly include topical emollients, corticosteroids, and immunosuppressive agents. However, long-term epicutaneous application of corticosteroid increases the risk of recurrence and results in telangiectasia, petechiae, skin atrophy and thinning. 2 Thus, researchers have moved toward the discovery of alternative therapeutic agents for AD from traditional Chinese medicine or natural products with better long-term benefits and less side effects. 8 Luteolin, a food‐derived flavonoid, which is present in medicinal plants worldwide, was reported to have many noteworthy pharmacological properties, including anti-inflammatory, anti-oxidant and anti-allergic effects. 9–11 One previous pre-clinical study showed that luteolin suppressed dry skin induced spontaneous scratching behavior in mice via inhibiting IgE-mediat -Abstract Truncated-